Why is the Synergy Thrombosis Prevention Program important?
Venous thrombosis (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolisms (PEs), occurs far too frequently with 375,000 to 425,000 new cases diagnosed, and medically treated, annually1. “Over one-half million hospitalizations occur in the US each year1” to treat VTE and “roughly 1 out of 10 hospital deaths are related to PE”2, many of which were not diagnosed prior to death2. Conservatively, these cases cost the US healthcare system $7 – 10 billion each year.1 “Estimates of the total economic impact of VTE, including the value of lost economic output due to premature mortality is as high as $69 billion per year”.1
- Grosse, Scott D., Nelson, Richard E., Nyarko, Kwame A., Raskob, Gary E., Richardson, Lisa C. “The Economic Burden of Incident Venous Thromboembolism in the United States: A Review of the Estimated Attributed Healthcare Costs.” Thrombosis Research, vol. 137, no. January 2016, Nov. 2015, https://doi.org/https://doi.org/10.1016/j.thromres.2015.11.033.
- Office of the Surgeon General (US); National Heart, Lung, and Blood Institute (US). The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville (MD): Office of the Surgeon General (US); 2008. SECTION I: Deep Vein Thrombosis and Pulmonary Embolism as Major Public Health Problems. Available from: https://www.ncbi.nlm.nih.gov/books/NBK44181/
The Benefits of Partnering with Synergy
The Synergy Thrombosis Prevention Program is Synergy’s response to this call to action to prevent episodes of VTE. Through a combination of high-quality, state-of-the-art equipment, delivery of a structured educational program, and access to knowledgeable clinical and customer service team members, Synergy is working with providers, health plans and health systems to reduce the number of VTE cases experienced by our partners’ patients/plan members. By utilizing an evidence-based, proactive approach, Synergy provides the following benefits for stakeholders: